VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

AAN 2021 | Rimegepant to treat acute migraine in patients with cardiovascular risk factors

Susan Hutchinson, MD, Orange County Migraine & Headache Center, Irvine, CA, explains the study evaluating rimegepant in adults with cardiovascular risk factors. In the United States, there are over 3.5 million of Americans for whom the triptans, which are used for acute treatment of migraine, are contraindicated due to cardiac risk factors. A multicenter, open-label, long-term study (NCT03266588) analyzed the safety and tolerability of using rimegepant in patients with or without associated risk factors. Dr Hutchinson shares the findings from the study and the impact on many patients with migraine. This interview took place during the American Academy of Neurology (AAN) 2021 Annual Meeting.


Consultant/advisory board member: Alder/Lundbeck, Allergan/AbbVie, Amgen, Biohaven, Currax, electroCore, Impel, Lilly, Novartis, Teva, Theranica, Upsher-Smith
Speaker’s bureau: AbbVie, Amgen, electroCore, Lilly, Lundbeck, Novartis, Teva, Theranica, Upsher-Smith